Clinical Trials Browser

Phase 2 × Gemcitabine × Breast × Clear all

NCT07203729 2026-03-16

The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis

Phase 2 Recruiting

Breast Neoplasms

NCT06449222 2026-02-25

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

Phase 2 Active not recruiting

Triple Negative Breast Neoplasms

NCT05601440 2026-02-11

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT06027268 2026-02-03

ToPCourT

Phase 2 Active not recruiting

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT06492759 2025-12-16

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT04659603 2025-10-01

CARMEN-BT01

Phase 2 Terminated

50 enrolled 20 charts

BreastGastrointestinal

Breast Cancer Metastatic

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT02252887 2025-07-25

Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy

Phase 2 Completed

Metastatic HER2-Positive Breast Cancer

NCT02755272 2025-07-04

A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06533722 2025-06-10

Adaptive Therapy for Post-Second-Line Advanced Breast Cancer

Phase 2 Completed

HER2-negative Metastatic Breast Cancer

NCT01815242 2025-02-27

ADAPT

Phase 2 Completed

Breast Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

Phase 2 Active not recruiting

Breast Neoplasms

NCT06102824 2024-11-25

ORIENTA

Phase 2 Recruiting

HER2-negative Breast Cancer

NCT03678883 2024-11-07

9-ING-41 in Patients with Advanced Cancers

Phase 2 Active not recruiting

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT03839823 2024-10-09

RIGHT Choice

Phase 2 Completed

222 enrolled 17 charts

Breast Neoplasms

NCT06531447 2024-08-01

First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients

Phase 2 Active not recruiting

Fibrosis Of Extraocular Muscles, Congenital, 3A, with or without Extraocular Involvement, Breast Neoplasms

NCT04464174 2024-07-26

PATHFINDER

Phase 2 Completed

Triple Negative Breast Neoplasms

NCT03887130 2024-04-30

Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer

Phase 2 Completed

152 enrolled 14 charts

Breast Neoplasms

NCT04739670 2024-03-01

BELLA

Phase 2 Unknown

Recurrence, Triple Negative Breast Neoplasms

NCT00679029 2023-12-11

Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer

Phase 2 Terminated

15 enrolled 9 charts

Breast Neoplasms

NCT04262804 2023-08-22

A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Phase 2 Unknown

Breast Cancer Metastatic

NCT05809895 2023-07-24

AdvanTIG-211

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT00244933 2023-06-22

Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast Cancer

Phase 2 Completed

19 enrolled 5 charts

Breast Neoplasms

NCT03567720 2023-06-01

Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

Phase 2 Unknown

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT00323063 2023-03-29

Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer

Phase 2 Terminated

49 enrolled 11 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00128856 2023-03-06

Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients

Phase 2 Completed

Breast Neoplasms, Disease

NCT02341911 2022-04-20

TNBC

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04745975 2022-04-20

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT02978716 2022-03-23

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)

Phase 2 Terminated

102 enrolled 51 charts

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT00193206 2021-11-23

Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer

Phase 2 Completed

123 enrolled 8 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00193050 2021-10-26

Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer

Phase 2 Completed

110 enrolled 8 charts

Breast Neoplasms

NCT02435680 2021-06-21

TNBC

Phase 2 Completed

50 enrolled 22 charts

Advanced Triple Negative Breast Cancer (TNBC) With High TAMs

NCT00470249 2021-02-01

Carboplatin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Phase 2 Terminated

Breast Neoplasms, Breast Neoplasms, Male

NCT04681911 2020-12-23

Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT04517292 2020-08-18

GEP

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02263495 2020-07-14

EG_PG

Phase 2 Completed

Breast Neoplasms

NCT02538432 2019-11-04

Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors

Phase 2 Withdrawn

BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms, Disease Progression

NCT04143906 2019-10-30

Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT01606748 2019-09-30

A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin

Phase 2 Completed

35 enrolled 23 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT00191243 2019-09-12

Docetaxel vs. Docetaxel-Gemcitabine in Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT00462865 2019-04-09

Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse

Phase 2 Terminated

18 enrolled 8 charts

Breast Neoplasms

NCT00403130 2019-02-20

Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer

Phase 2 Completed

31 enrolled 11 charts

Breast Neoplasms

NCT00201760 2017-12-27

Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer

Phase 2 Completed

10 enrolled 9 charts

Breast Neoplasms, Neoplasm Metastasis

NCT00503906 2017-05-12

Abraxane, Avastin, and Gemcitabine as First-Line Therapy for Patients With Metastatic Breast Cancer

Phase 2 Completed

30 enrolled 10 charts

Breast Neoplasms

NCT00662129 2017-04-17

Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer

Phase 2 Completed

50 enrolled 11 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00618826 2017-04-14

A Study of Biweekly Gemcitabine, Paclitaxel, and Avastin in Patients With Metastatic Breast Cancer

Phase 2 Completed

14 enrolled 8 charts

Breast Neoplasms

NCT00006007 2016-12-07

LY231514 Plus Gemcitabine in Treating Women With Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT00059852 2016-12-07

Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and/or a Taxane

Phase 2 Completed

Breast Neoplasms, Breast Neoplasms, Male

NCT00002998 2016-07-13

Gemcitabine and Cisplatin in Treating Patients With Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT00813956 2016-03-17

A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer

Phase 2 Completed

Triple Negative Breast Neoplasms